Microneedle vaccination elicits superior protection and antibody response over intranasal vaccination against swine-origin influenza a (H1N1) in mice

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Shin, Ju Hyung ^a   Park, Jae Keun ^b   Lee, Dong Hun ^b   Quan, Fu Shi ^c   Song, Chang Seon ^b   Kim, Yeu Chun ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Konkuk University   (South Korea)

^c Kyung Hee University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

2009 H1N1 INFLUENZA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; HEMAGGLUTINATION INHIBITION; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA VACCINATION; MICRONEEDLE; MOUSE; NONHUMAN; SURVIVAL RATE; VIRUS REPLICATION; WEIGHT REDUCTION; ANIMAL; ANTIBODY PRODUCTION; BLOOD; DISEASE MODEL; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INTRANASAL DRUG ADMINISTRATION; MORTALITY; ORTHOMYXOVIRIDAE INFECTIONS; PATHOLOGY; PIG;

MUS; SUIDAE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION INHIBITION TESTS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MICE; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL RATE; SWINE; VACCINES, INACTIVATED;

EID: 84939182859     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130684     Document Type: Article

References (57)

1. Holmgren J, Svennerholm AM. Vaccines against mucosal infections. Curr Opin Immunol. 2012; 24 (3): 343-53. doi:10.1016/j.coi.2012.03.014 PMID: 22580196.
2. Girard MP, Cherian T, Pervikov Y, Kieny MP. A review of vaccine research and development: human acute respiratory infections. Vaccine. 2005; 23(50): 5708-24. doi:10.1016/j.vaccine.2005.07.046 PMID: 16154667.
3. Girard MP, Tam JS, Assossou OM, Kieny MP. The 2009 A (H1N1) influenza virus pandemic: A review. Vaccine. 2010; 28(31): 4895-902. doi:10.1016/j.vaccine.2010.05.031 PMID: 20553769.
4. Yu H, Cowling BJ, Feng L, Lau EH, Liao Q, Tsang TK, et al. Human infection with avian influenza A H7N9 virus: an assessment of clinical severity. The Lancet. 2013; 382(9887): 138-45. doi:10.1016/S0140-6736(13)61207-6 PMID: 23803487
5. Palese P. Influenza: old and new threats. Nat Med. 2004; 10: S82-S7. PMID: 15577936
6. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-Analysis. Lancet Infect Dis. 2012; 12(1): 36-44. doi:10.1016/s1473-3099 (11)70295-x PMID: WOS: 000298515900018.
7. Amorij J-P, Kersten GF, Saluja V, Tonnis WF, Hinrichs WL, Slütter B, et al. Towards tailored vaccine delivery: Needs, challenges and perspectives. J Controlled Release. 2012; 161(2): 363-76. doi:10. 1016/j.jconrel.2011.12.039 PMID: 22245687
8. Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv Drug Del Rev. 2006; 58(1): 68-89. PMID: 16564111
9. Kim YC, Jarrahian C, Zehrung D, Mitragotri S, Prausnitz MR. Delivery systems for intradermal vaccination. Curr Top Microbiol Immunol. 2012; 351: 77-112. doi:10.1007/82-2011-123 PMID: 21472533; PubMed Central PMCID: PMC3173582.
10. Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol. 2012; 12(8): 592-605. doi:10.1038/nri3251 PMID: 22828912.
11. Amorij JP, Hinrichs WLJ, Frijlink HW, Wilschut JC, Huckriede A. Needle-free influenza vaccination. Lancet Infect Dis. 2010; 10(10): 699-711. doi:10.1016/s1473-3099(10)70157-2 PMID: WOS: 000282911200018.
12. Mitragotri S. Immunization without needles. Nat Rev Immunol. 2005; 5(12): 905-16. doi:10.1038/nri1728 PMID: 16239901.
13. Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012. doi:10.1016/j.addr.2012.04.005 PMID: 22575858; PubMed Central PMCID: PMC3419303.
14. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-Adjuvanted vaccine. New Engl J Med. 2009; 361(25): 2424-35. doi:10.1056/NEJMoa0907650 PMID: 19745215
15. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoché MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. The Lancet. 2010; 375(9708): 41-8. doi:10.1016/S0140-6736(09)62026-2 PMID: 20018365
16. Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release. 2010; 142(2): 187-95. doi:10.1016/j.jconrel.2009.10.013 PMID: 19840825; PubMed Central PMCID: PMC2823933.
17. Gill HS, Denson DD, Burris BA, Prausnitz MR. Effect of microneedle design on pain in human subjects. The Clinical journal of pain. 2008; 24(7): 585. doi:10.1097/AJP.0b013e31816778f9 PMID: 18716497
18. Quan FS, Kim YC, Vunnava A, Yoo DG, Song JM, Prausnitz MR, et al. Intradermal Vaccination with Influenza Virus-Like Particles by Using Microneedles Induces Protection Superior to That with Intramuscular Immunization. J Virol. 2010; 84(15): 7760-9. doi:10.1128/jvi.01849-09 PMID: WOS: 000279989800034.
19. Weldon WC, Martin MP, Zarnitsyn V, Wang B, Koutsonanos D, Skountzou I, et al. Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity. Clin Vaccine Immunol. 2011; 18(4): 647-54. doi:10.1128/CVI.00435-10 PMID: 21288996; PubMed Central PMCID: PMC3122571.
20. Song JM, Kim YC, O E, Compans RW, Prausnitz MR, Kang SM. DNA vaccination in the skin using microneedles improves protection against influenza. Mol Ther. 2012; 20(7): 1472-80. doi:10.1038/mt. 2012.69 PMID: 22508490; PubMed Central PMCID: PMC3392990.
21. Murphy KM. Janeway's Immunobiology 8th Ed: Garland Science; 2012.
22. Davis S. Nasal vaccines. Adv Drug Del Rev. 2001; 51(1): 21-42.
23. Buonagurio DA, Bechert TM, Yang CF, Shutyak L, D'Arco GA, Kazachkov Y, et al. Genetic stability of live, cold-Adapted influenza virus components of the FluMist/CAIV-T vaccine throughout the manufacturing process. Vaccine. 2006; 24(12): 2151-60. doi:10.1016/j.vaccine.2005.11.007 PMID: 16413951.
24. Carter NJ, Curran MP. Live Attenuated Influenza Vaccine (FluMist; Fluenz). Drugs. 2011; 71(12): 1591-622. doi:10.2165/11206860-000000000-00000 PMID: 21861544
25. Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J Control Release. 2007; 117 (2): 227-37. doi:10.1016/j.jconrel.2006.10.017 PMID: 17169459; PubMed Central PMCID: PMC1853346.
26. Quan FS, Kim YC, Yoo DG, Compans RW, Prausnitz MR, Kang SM. Stabilization of Influenza Vaccine Enhances Protection by Microneedle Delivery in the Mouse Skin. PLoS One. 2009; 4(9). doi:10.1371/journal.pone.0007152 PMID: WOS: 000270176200007.
27. Kim Y-C, Yoo D-G, Compans RW, Kang S-M, Prausnitz MR. Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles. J Controlled Release. 2013.
28. Tobita K, Sugiura A, Enomoto C, Furuyama M. Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin. Med Microbiol Immunol. 1975; 162(1): 9-14. PMID: 1214709
29. Ohmit SE, Thompson MG, Petrie JG, Thaker SN, Jackson ML, Belongia EA, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2013: cit736.
30. Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med. 2013; 64: 189-202. doi:10.1146/annurev-med-120611-145115 PMID: 23327522.
31. Subbarao K, Matsuoka Y. The prospects and challenges of universal vaccines for influenza. Trends Microbiol. 2013.
32. Matsuo K, Hirobe S, Okada N, Nakagawa S. Frontiers of transcutaneous vaccination systems: Novel technologies and devices for vaccine delivery. Vaccine. 2013.
33. Nestle FO, Di Meglio P, Qin J-Z, Nickoloff BJ. Skin immune sentinels in health and disease. Nature Reviews Immunology. 2009; 9(10): 679-91. doi:10.1038/nri2622 PMID: 19763149
34. Pavot V, Rochereau N, Genin C, Verrier B, Paul S. New insights in mucosal vaccine development. Vaccine. 2012; 30(2): 142-54. doi:10.1016/j.vaccine.2011.11.003 PMID: 22085556
35. Sullivan SP, Koutsonanos DG, Del Pilar Martin M, Lee JW, Zarnitsyn V, Choi SO, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med. 2010; 16(8): 915-20. doi:10.1038/nm. 2182 PMID: 20639891; PubMed Central PMCID: PMC2917494.
36. Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine. 2003; 21(23): 3212-8. PMID: 12804850
37. Wareing M, Tannock G. Live attenuated vaccines against influenza; an historical review. Vaccine. 2001; 19(25): 3320-30. PMID: 11348696
38. Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, Prausnitz MR. Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis. 2010; 201(2): 190-8. doi:10.1086/649228 PMID: 20017632; PubMed Central PMCID: PMC2798016.
39. Quan FS, Kim YC, Compans RW, Prausnitz MR, Kang SM. Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J Control Release. 2010; 147(3): 326-32. doi:10.1016/j.jconrel.2010.07.125 PMID: 20692307; PubMed Central PMCID: PMC2975779.
40. Ichinohe T, Tamura S-i, Kawaguchi A, Ninomiya A, Imai M, Itamura S, et al. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis. 2007; 196(9): 1313-20. PMID: 17922395
41. McGhee J, Czerkinsky C, Mestecky J. Mucosal vaccines: an overview. Mucosal Immunol. 1999; 2: 741-57.
42. Yang P, Duan Y, Zhang P, Li Z, Wang C, Dong M, et al. Multiple-clade H5N1 influenza split vaccine elicits broad cross protection against lethal influenza virus challenge in mice by intranasal vaccination. PLoS One. 2012; 7(1): e30252. doi:10.1371/journal.pone.0030252 PMID: 22279575
43. Eyles JE, Williamson ED, Alpar HO. Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: studies on the effect of vehicle volume. Int J Pharm. 1999; 189(1): 75-9. PMID: 10518687
44. Balmelli C, Roden R, Potts A, Schiller J, De Grandi P, Nardelli-Haefliger D. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol. 1998; 72(10): 8220-9. PMID: 9733865
45. Baz M, Samant M, Zekki H, Tribout-Jover P, Plante M, Lanteigne A-M, et al. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice. Clin Vaccine Immunol. 2012; 19(2): 209-18. doi:10.1128/CVI.05441-11 PMID: 22190392
46. Richert LE, Servid AE, Harmsen AL, Rynda-Apple A, Han S, Wiley JA, et al. A virus-like particle vaccine platform elicits heightened and hastened local lung mucosal antibody production after a single dose. Vaccine. 2012; 30(24): 3653-65. doi:10.1016/j.vaccine.2012.03.035 PMID: 22465748
47. Li Y, Li J, Zhang X, Ding J, Mao S. Non-ionic surfactants as novel intranasal absorption enhancers: in vitro and in vivo characterization. Drug Deliv. 2014; (0): 1-8.
48. Oh Y-K, Park J-S, Yoon H, Kim C-K. Enhanced mucosal and systemic immune responses to a vaginal vaccine coadministered with RANTES-expressing plasmid DNA using in situ-gelling mucoadhesive delivery system. Vaccine. 2003; 21(17): 1980-8.
49. Xu X, Shen Y, Wang W, Sun C, Li C, Xiong Y, et al. Preparation and in vitro characterization of thermosensitive and mucoadhesive hydrogels for nasal delivery of phenylephrine hydrochloride. Eur J Pharm Biopharm. 2014; 88(3): 998-1004. doi:10.1016/j.ejpb.2014.08.015 PMID: 25257714
50. Chen X, Zhi F, Jia X, Zhang X, Ambardekar R, Meng Z, et al. Enhanced brain targeting of curcumin by intranasal administration of a thermosensitive poloxamer hydrogel. J Pharm Pharmacol. 2013; 65 (6): 807-16. doi:10.1111/jphp.12043 PMID: 23647674
51. Lehr C-M, Bouwstra JA, Schacht EH, Junginger HE. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm. 1992; 78(1): 43-8.
52. Ugwoke MI, Agu RU, Jorissen M, Augustijns P, Sciot R, Verbeke N, et al. Toxicological investigations of the effects carboxymethylcellulose on ciliary beat frequency of human nasal epithelial cells in primary suspension culture and in vivo on rabbit nasal mucosa. Int J Pharm. 2000; 205(1): 43-51.
53. Roy S, Pal K, Anis A, Pramanik K, Prabhakar B. Polymers in mucoadhesive drug-delivery systems: a brief note. Designed monomers and polymers. 2009; 12(6): 483-95.
54. Madsen F, Eberth K, Smart JD. A rheological examination of the mucoadhesive/mucus interaction: the effect of mucoadhesive type and concentration. J Controlled Release. 1998; 50(1): 167-78.
55. Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Vaccines for Pandemic Influenza: Springer; 2009. p. 369-93.
56. Song JY, Cheong HJ, Noh JY, Yang TU, Seo YB, Hong K-W, et al. Long-Term immunogenicity of the influenza vaccine at reduced intradermal and full intramuscular doses among healthy young adults. Clinical and experimental vaccine research. 2013; 2(2): 115-9. doi:10.7774/cevr.2013.2.2.115 PMID: 23858402
57. Budimir N, Haan A, Meijerhof T, Gostick E, Price DA, Huckriede A, et al. Heterosubtypic cross-protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration. Influenza Other Respi Viruses. 2013; 7(6): 1202-9.